FDA approves antibody to protect infants from RSV
1 year ago
191
The U.S. Food and Drug Administration approved Nirsevimab to protect newborns from Respiratory Syncytial Virus, or RSV, on Monday. Nirsevimab, which will be sold under the brand name Beyfortus, is not a vaccine. Instead, Nirsevimab is a form of passive immunity. It’s a ready-made antibody that can bind to the virus and block it from infecting healthy cells. It will be given as a single injection to an infant before RSV season, which usually peaks in the fall and winter months. The FDA approval also allows a second injection for infants up to 24 months of age who remain vulnerable through their second RSV season.
Loading comments...
-
UPCOMING
BonginoReport
1 hour agoKamala Harris' First Campaign Ad Is Very Cringe (Ep.08) - 07/26/24
4 -
LIVE
Game On!
8 hours agoRanking NFL Quarterbacks 2024 Season!
797 watching -
5:22
JoBlo Originals
18 hours agoDeadpool & Wolverine NO SPOILERS Review!
6502 -
8:00
The Gun Collective
17 hours agoTech Giants AGREE - New YouTube Gun Policies are INSANE!
7.23K40 -
7:17
Dr. Nick Zyrowski
10 days agoIncredible Health Benefits of NAC ( N-Acetyl Cysteine)
1.8K1 -
10:23
Freakin' Reviews
1 day agoZoku Quick Pop Maker Review: Popsicles in 7 Minutes?
9.27K4 -
1:11:38
TheMonicaCrowleyPodcast
16 hours agoThe Monica Crowley Podcast: Obama’s Grip Slips
11.3K7 -
31:38
Science & Futurism with Isaac Arthur
23 hours ago $0.03 earnedSelf-Repairing Machines
4.83K4 -
44:07
Degenerate Jay
1 day ago $0.03 earnedHugh Jackman's Wolverine Made Me A Better Person
12.8K3 -
19:31
GameLeap RAID Shadow Legends
18 hours ago#1 BEST RARE Champion EVERY FACTION (Build for Faction Wars) - Raid: Shadow Legends Guide
12.2K2